TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015
Proposal to move the existing guidance to the static list
The planned date for review of the above guidance is February 2015.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
At this time, there is no new evidence available that would lead to a change in the existing recommendations. Consequently, we propose that TA274 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see Appendix A for a list of organisations that we have contacted.
This page was last updated: 18 February 2015